Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
Cash Flow Statement
Cash Flow Statement
Amylyx Pharmaceuticals Inc
| Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||||||||||
| Net Income |
(79)
|
(68)
|
(88)
|
(121)
|
(153)
|
(184)
|
(198)
|
(149)
|
(73)
|
2
|
49
|
(71)
|
(166)
|
(259)
|
(302)
|
(219)
|
(188)
|
(149)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Stock-Based Compensation |
1
|
2
|
3
|
7
|
12
|
17
|
22
|
25
|
29
|
34
|
37
|
40
|
39
|
36
|
33
|
30
|
28
|
28
|
|
| Other Non-Cash Items |
9
|
7
|
8
|
10
|
12
|
16
|
20
|
21
|
22
|
25
|
27
|
140
|
148
|
181
|
179
|
66
|
57
|
22
|
|
| Cash Taxes Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
5
|
6
|
7
|
4
|
2
|
1
|
0
|
0
|
0
|
|
| Change in Working Capital |
7
|
5
|
5
|
8
|
5
|
9
|
(2)
|
(17)
|
(40)
|
(80)
|
(66)
|
(54)
|
(42)
|
(18)
|
(46)
|
(55)
|
(36)
|
(28)
|
|
| Cash from Operating Activities |
(62)
N/A
|
(55)
+11%
|
(75)
-35%
|
(103)
-37%
|
(136)
-33%
|
(158)
-16%
|
(180)
-14%
|
(144)
+20%
|
(89)
+38%
|
(51)
+42%
|
12
N/A
|
17
+38%
|
(59)
N/A
|
(95)
-62%
|
(168)
-76%
|
(207)
-23%
|
(166)
+20%
|
(154)
+7%
|
|
| Investing Cash Flow | |||||||||||||||||||
| Capital Expenditures |
(0)
|
(0)
|
(0)
|
(1)
|
(2)
|
(2)
|
(3)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
(37)
|
(36)
|
(36)
|
(36)
|
(0)
|
|
| Other Items |
0
|
(49)
|
(46)
|
(145)
|
(139)
|
(6)
|
(236)
|
(81)
|
37
|
(156)
|
93
|
38
|
(114)
|
68
|
112
|
67
|
119
|
50
|
|
| Cash from Investing Activities |
(0)
N/A
|
(49)
-29 822%
|
(46)
+6%
|
(146)
-214%
|
(141)
+3%
|
(8)
+94%
|
(239)
-2 890%
|
(84)
+65%
|
35
N/A
|
(157)
N/A
|
92
N/A
|
37
-60%
|
(115)
N/A
|
32
N/A
|
76
+139%
|
31
-59%
|
83
+167%
|
50
-40%
|
|
| Financing Cash Flow | |||||||||||||||||||
| Net Issuance of Common Stock |
30
|
135
|
135
|
336
|
336
|
201
|
435
|
237
|
239
|
240
|
7
|
5
|
3
|
2
|
2
|
67
|
67
|
261
|
|
| Net Issuance of Debt |
42
|
26
|
26
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other |
3
|
(0)
|
(3)
|
(3)
|
(6)
|
(3)
|
(3)
|
(5)
|
(5)
|
(5)
|
(3)
|
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(3)
|
|
| Cash from Financing Activities |
75
N/A
|
161
+115%
|
159
-1%
|
333
+110%
|
330
-1%
|
199
-40%
|
432
+117%
|
232
-46%
|
235
+1%
|
235
+0%
|
4
-98%
|
3
-26%
|
1
-52%
|
0
-63%
|
0
-26%
|
66
+18 831%
|
66
0%
|
257
+291%
|
|
| Change in Cash | |||||||||||||||||||
| Effect of Foreign Exchange Rates |
0
|
0
|
0
|
(0)
|
(0)
|
(1)
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
1
|
0
|
|
| Net Change in Cash |
12
N/A
|
56
+359%
|
37
-33%
|
84
+126%
|
53
-38%
|
32
-40%
|
13
-59%
|
4
-65%
|
181
+3 950%
|
28
-85%
|
108
+291%
|
56
-48%
|
(173)
N/A
|
(63)
+64%
|
(92)
-47%
|
(110)
-20%
|
(16)
+85%
|
153
N/A
|
|
| Free Cash Flow | |||||||||||||||||||
| Free Cash Flow |
(63)
N/A
|
(56)
+11%
|
(75)
-35%
|
(103)
-38%
|
(138)
-33%
|
(161)
-16%
|
(182)
-14%
|
(147)
+20%
|
(91)
+38%
|
(53)
+42%
|
11
N/A
|
15
+45%
|
(60)
N/A
|
(132)
-121%
|
(204)
-55%
|
(243)
-19%
|
(202)
+17%
|
(155)
+23%
|
|